These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 26058416)
1. Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer. Mi JQ; Chen SJ; Zhou GB; Yan XJ; Chen Z J Intern Med; 2015 Dec; 278(6):627-42. PubMed ID: 26058416 [TBL] [Abstract][Full Text] [Related]
2. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642 [TBL] [Abstract][Full Text] [Related]
3. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Lo-Coco F; Hasan SK Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012 [TBL] [Abstract][Full Text] [Related]
4. Acute promyelocytic leukemia: a paradigm for differentiation therapy. Grimwade D; Mistry AR; Solomon E; Guidez F Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254 [TBL] [Abstract][Full Text] [Related]
5. [Pathogenesis of Acute Promyelocytic Leukemia]. Matsushita H Rinsho Byori; 2015 May; 63(5):631-42. PubMed ID: 26524903 [TBL] [Abstract][Full Text] [Related]
6. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells. Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552 [TBL] [Abstract][Full Text] [Related]
7. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811 [TBL] [Abstract][Full Text] [Related]
8. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia. Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453 [TBL] [Abstract][Full Text] [Related]
9. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688 [TBL] [Abstract][Full Text] [Related]
10. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181 [TBL] [Abstract][Full Text] [Related]
12. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia. Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155 [TBL] [Abstract][Full Text] [Related]
13. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide. Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245 [TBL] [Abstract][Full Text] [Related]
14. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia. Jing Y Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934 [TBL] [Abstract][Full Text] [Related]
15. Histone deacetylases and transcriptional therapy with their inhibitors. Pandolfi PP Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S17-9. PubMed ID: 11587360 [TBL] [Abstract][Full Text] [Related]
16. Advances in therapies for acute promyelocytic leukemia. Kamimura T; Miyamoto T; Harada M; Akashi K Cancer Sci; 2011 Nov; 102(11):1929-37. PubMed ID: 21790894 [TBL] [Abstract][Full Text] [Related]
17. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821 [TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Kitamura K; Hoshi S; Koike M; Kiyoi H; Saito H; Naoe T Br J Haematol; 2000 Mar; 108(4):696-702. PubMed ID: 10792271 [TBL] [Abstract][Full Text] [Related]
19. What is the role of arsenic in newly diagnosed APL? Tallman MS Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605 [TBL] [Abstract][Full Text] [Related]
20. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A. Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]